Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery methodReport as inadecuate

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method - Download this document for free, or read online. Document in PDF available to download.

Respiratory Research

, 12:153

First Online: 01 December 2011Received: 06 September 2011Accepted: 21 November 2011


Conventional parenteral injection of vaccines is limited in its ability to induce locally-produced immune responses in the respiratory tract, and has logistical disadvantages in widespread vaccine administration. Recent studies suggest that intranasal delivery or vaccination in the respiratory tract with recombinant viral vectors can enhance immunogenicity and protection against respiratory diseases such as influenza and tuberculosis, and can offer more broad-based generalized protection by eliciting durable mucosal immune responses. Controlled aerosolization is a method to minimize vaccine particle size and ensure delivery to the lower respiratory tract. Here, we characterize the dynamics of aerosolization and show the effects of vaccine concentration on particle size, vector viability, and the actual delivered dose of an aerosolized adenoviral vector. In addition, we demonstrate that aerosol delivery of a recombinant adenoviral vaccine encoding H1N1 hemagglutinin is immunogenic and protects ferrets against homologous viral challenge. Overall, aerosol delivery offers comparable protection to intramuscular injection, and represents an attractive vaccine delivery method for broad-based immunization campaigns.

Electronic supplementary materialThe online version of this article doi:10.1186-1465-9921-12-153 contains supplementary material, which is available to authorized users.

Alida Ault, Satheesh K Sivasubramani contributed equally to this work.

Download fulltext PDF

Author: Chad J Roy - Alida Ault - Satheesh K Sivasubramani - J Patrick Gorres - Chih-Jen Wei - Hanne Andersen - Jason Gall - Mar


Related documents